Ventures Fund Iv General Pa... Net Worth

Insiders trading at Kaleido Biosciences Inc

Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm et Ventures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.

What does Kaleido Biosciences Inc do?

the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.

Kaleido Biosciences Inc executives and stock owners

Kaleido Biosciences Inc executives and other stock owners filed with the SEC include:

• Jerald Korn,
  General Counsel, Corporate Secretary
• Katharine Knobil,
  Chief Medical Officer and Head of Research and Development
• William E. Duke Jr.,
  Chief Financial Officer
• Daniel L. Menichella B.A., M.B.A.,
  Pres, CEO & Director
• Jean Mixer,
  Independent Director
• Theo Melas-Kyriazi,
  Independent Director
• Michael Bonney,
  Chairman of the Board
• Anthony Quinn,
  Independent Director
• Grady Burnett,
  Independent Director
• Bonnie Bassler,
  Independent Director
• Anne Prener,
  Independent Director
• William Duke,
  Chief Financial Officer
• Daniel Menichella,
  President, Chief Executive Officer, Principal Executive Officer
• Dr. Alison Long M.D., Ph.D.,
  Chief Medical Officer
• Dr. Mark A. Wingertzahn Ph.D.,
  Sr. VP of R&D and Head of Devel.
• Susan Stewart J.D.,
  Chief Regulatory Affairs – Advisor
• Dr. Johan Van Hylckama Vlieg Ph.D.,
  Chief Scientific Officer
• Kimberly Hocknell,
  Sr. VP of Technical Operations
• Jerald Korn J.D.,
  COO, Gen. Counsel & Corp. Sec.
• Dr. Geoffrey von Maltzahn Ph.D.,
  Co-Founder & Director
• Hylckama Vlieg Johan Van,
  Chief Scientific Officer
• Ventures Fund Iv General Pa...,
  
• Joshua T Brumm,
  See Remarks
• Alison Frances Lawton,
  See Remarks
• Maltzahn Geoffrey Von,
  Director
• Ventures Fund V General Par...,
  
• Ventures Fund Iv General Pa...,
  
• Ventures Fund Iv General Pa...,
  
• Alison S Long,
  Chief Medical Officer